It's obvious that the company has a good shot at returning to growth.

Biogen reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance as cost-cutting efforts showed progress and sales of its breakthrough Alzheimer's drug, ...

Biogen reported third-quarter revenue and adjusted earnings that topped expectations. The company also raised its full-year profit guidance. Sales of its breakthrough Alzheimer's drug, Leqembi, along ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Ahead of reporting its third ...

Biogen now expects full-year adjusted earnings to come in at $15.75 to $16.25 per share, up from a previous forecast of $15 to $16 per share. The biotech company also expects 2024 sales to decline by ...